Drug intelligence / Profile preview

BA1106

Development stage: Phase 1
Lead developer: Boan Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BA1106 is a human anti-CD25 monoclonal antibody developed by Boan Biotech. It targets the interleukin-2 receptor alpha chain (IL2RA) and functions by depleting Treg cells in the tumor microenvironment through antibody-dependent cellular cytotoxicity (ADCC), thereby increasing the number of effector T cells. Unlike other anti-CD25 antibodies, BA1106 does not block the IL-2 signaling pathway, allowing it to specifically deplete Treg cells without impairing effector T cells. It has shown therapeutic effects in both early-stage and advanced tumors and synergizes with anti-PD-1 antibodies.

Targets

IL2RA (Interleukin-2 receptor alpha subunit)

Beyond the preview

Go deeper on BA1106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BA1106.

Explore the full profile